Anzeige
Mehr »
Login
Dienstag, 14.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 906327 | ISIN: FR0000033599 | Ticker-Symbol: LXB
Frankfurt
14.01.25
08:07 Uhr
4,140 Euro
+0,200
+5,08 %
Branche
Konsumgüter
Aktienmarkt
Sonstige
1-Jahres-Chart
LEXIBOOK LINGUISTIC ELECTRONIC SYSTEM SA Chart 1 Jahr
5-Tage-Chart
LEXIBOOK LINGUISTIC ELECTRONIC SYSTEM SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,9804,24023:00
GlobeNewswire (Europe)
48 Leser
Artikel bewerten:
(0)

LEXIBOOK: Results of the Reopened Offer in connection with Doodle's public tender offer (the "Tender Offer") for shares

Finanznachrichten News

Tuesday, January 14,

Results of the Reopened Offer in connection with Doodle's public tender offer (the "Tender Offer") for shares

Lexibook (ISIN FR0000033599 - ALLEX), a European player in electronic leisure products sold under license, announces the result of the reopened offer (the "Reopened Offer") initiated by Doodle (the "Offeror") for the shares of Lexibook, and published by the Autorité des marchés financiers (the "AMF").

Following the closure of the Reopened Offer, 206,026 Lexibook shares were tendered. As a result, the concert consisting of the members of the Le Cottier family group and the companies Doodle and Lawrence Rosen LLC, holds 6,101,028 LEXIBOOK shares representing 8,428,110 voting rights, i.e. 78.59% of the capital and at least 83.46% of the voting rights of this company, according to the following breakdown:

Actions% capitalVoting rights% voting rights
Doodle3 637 22246,853 637 22236,02
Emeric Le Cottier1 187 02915,292 329 37523,07
Emmanuel Le Cottier1 154 60714,872 271 87922,50
Luc Le Cottier122 1701,57189 6341,88
Total Le Cottier family group6 101 02878,598 428 11083,46
Lawrence Rosen LLC0-0-
Total concert6 101 02878,598 428 11083,46

Following the declaration of threshold crossings as published on December 27, 2024 by the AMF1 and the maximum number of double voting rights outstanding as of December 23, 2024 (i.e. 5,604 Lexibook shares representing 11,208 voting rights), Doodle holds, at the close of the reopened Offer 6,101,028 shares and voting rights representing 78.59% of the share capital and at least 78.47% of the voting rights.2

Settlement and delivery of the Open Offer will take place on January 15, 2025.

The notice of results published by the AMF is available on the AMF website (www.amf-france.org). All documentation relating to the Offer is also available on the AMF (www.amf-france.org) and Lexibook (https://www.lexibook.com/fr/investisseurs.html) websites.

Gilbert Dupont acted as financial advisor to Doodle and Société Générale as financial advisor, presenting bank and guarantor of the takeover bid. D&A Strategic Corporate Finance acted as M&A advisor to Lexibook. McDermott Will & Emery and Delsol acted as legal advisors to Doodle and Lawence Rosen respectively.

Lexibook is also revising upwards its sales forecasts for the current financial year (ending March 31, 2025). By the end of December 2024, sales had reached around €64 million, outperforming initial expectations. As a result, the Company forecasts sales in excess of €69 million for 2025.

Nevertheless, the rapid deterioration in the euro/dollar exchange rate, which has fallen to as low as $1.02/euro, is likely to have a direct impact on the company's margins. Although this impact is under control for the current year, it could be felt more strongly next year if the trend continues, as the currency hedges in place are ineffective at the current rate.

About Lexibook

Lexibook®, owner of more than 22 registered brands such as Powerman®, Decotech®, Karaoke Micro Star®, Chessman®, Cyber Arcade®, Lexitab®, iParty®, FlashBoom®, etc., is the leader in intelligent electronic leisure products for children. This success is based on a proven strategy of combining strong international licenses with high value-added consumer electronics products. This strategy, complemented by a policy of constant innovation, enables the Group to flourish internationally and to constantly develop new product ranges under the Group's brands. With over 35 million products on the market, the company now sells a product every 10 seconds worldwide! Lexibook's share capital is made up of 7,763,319 shares listed on the Alternext market in Paris (Euronext). ISIN: FR0000033599 - ALLEX; ICB: 3743 - Consumer electronics. For further information: www.lexibook.com and www.decotech-lights.com.

Contact

LEXIBOOK - Aymeric Le Cottier - CEO - 01 73 23 23 48 / aymericlecottier@lexibook.com

WARNING
This press release, published for information purposes only, does not constitute a public offering. The offer document prepared by DOODLE, approved by the AMF on November 05, 2024 under no. 24-465, and the reply document approved by the AMF on November 05, 2024 under no. 24-466, as well as documents relating to other information about the offeror and the target, are available free of charge on the AMF (https://www.amf-france.org/) and Lexibook (https://www.lexibook.com/fr/investisseurs.html) websites.

1 Document 224C2847 dated December 27, 2024.
2 Corresponding to the loss of voting rights following the contribution undertakings signed on July 18, 2024, as specified in section 1.4.5 of the Information Memorandum.


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.